Terazosin for Dementia With Lewy Bodies

Part of paid clinical trials in Iowa City, Iowa.

Sponsor
Qiang Zhang
Study ID
NCT04760860
Phase
PHASE1/PHASE2
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Dementia With Lewy Bodies

Eligibility Criteria

Sex
ALL
Age
0 Years - 90 Years
Healthy Volunteers
Not accepted

Interventions

  • Terazosin Hydrochloride — DRUG
    In this double blind, randomized, placebo controlled phase I clinical trial, subjects randomized into the Terazosin group will receive Terazosin hydrochloride treatment for 15 weeks. Participants will start at 1mg daily for the first 6 week, then the dosage will be increased to 5mg daily over 3 weeks, and continued for the last 6 weeks.
  • Placebo — OTHER
    In this double blind, randomized, placebo controlled phase I clinical trial, subjects randomized into the control group will receive placebo for 15 weeks.

Study Details

The TZ-DLB trial will be a 3:2 (active:placebo) randomized, double-blind, placebo-controlled Pilot trial to evaluate the tolerability of terazosin for the treatment of dementia with Lewy bodies.

Key Dates

Start date
Oct 31, 2027
Status verified
Mar 2026
Primary completion
Oct 31, 2030
Completion
Dec 31, 2030

Study Design

Enrollment
40 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Placebo Comparator: Placebo Control Arm
    Participants in this arm will receive placebo during the trial for 15 weeks, the placebo will follow the same schedule as the Terazosin group; the placebo capsules will have the same appearance as the Terazosin capsules.
  • Experimental: Terazosin Arm
    Participants in this arm will receive Terazosin during the trial for 15 weeks. Participants will start at 1mg daily for the first 6 week, then the dosage will be increased to 5mg daily over 3 weeks, and continued for the last 6 weeks.

Primary Outcome Measure

Incidence of intervention-related adverse events between treatment arms [ Time Frame: 15 weeks ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
University of IowaIowa CityIowa52252
qiang zhang, MD
[email protected]
Jordan Schultz, PharmD
[email protected]
Nandakumar Narayanan, MD, PhD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Iowa City, IA

By research site
University of Iowa· Iowa City, IA

Related Studies